BRIEF-Pfizer gets FDA Approval for additional use of Xeljanz in Rheumatoid Arthritis

Mon Nov 18, 2013 4:51pm EST

Nov 18 (Reuters) - Pfizer : * Announces FDA approval of supplemental application to expand xeljanz

(tofacitinib citrate) labeling to include additional patient-reported

outcomes data for adults with moderately to severely active rheumatoid

arthritis * Source text for Eikon * Further company coverage